voltaren retard 100mg tableta s prodlouženým uvolňováním - search results

haleon hellas single member societe anonyme, under the distinctive title of haleon hellas, 274, kifissias ave, 15232 chalandri, athens, greece - diclofenac sodium - gel - diclofenac sodium 20 mg/g - topical products for joint and muscular pain

Canada - English - Health Canada

voltaren sr tablet (extended-release)

novartis pharmaceuticals canada inc - diclofenac sodium - tablet (extended-release) - 100mg - diclofenac sodium 100mg - other nonsteroidal antiimflammatory agents

Canada - English - Health Canada

voltaren suppository

novartis pharmaceuticals canada inc - diclofenac sodium - suppository - 50mg - diclofenac sodium 50mg - other nonsteroidal antiimflammatory agents

United States - English - NLM (National Library of Medicine)

voltaren- diclofenac sodium gel

unit dose services - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. voltaren® gel is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation risk summary use of nsaids, including voltaren® gel, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including voltaren® gel, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of voltaren® gel in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a backgrou